{"ModuleTitle": "Company Description", "CompanyName": "Oxford Immunotec Global PLC", "Symbol": "OXFD", "Address": "94C INNOVATION DRIVE MILTON PARK, ABINGDON, OX14 4RZ, United Kingdom", "Phone": "44 01235 442780", "Industry": "Biotechnology: In Vitro & In Vivo Diagnostic Substances", "Sector": "Health Care", "Region": "Europe", "CompanyDescription": "We are a global, high-growth diagnostics company focused on developing and\r\ncommercializing proprietary tests for immunology and infectious disease by\r\nleveraging the technological, product development, manufacturing, quality,\r\nregulatory, and sales and marketing capabilities we have developed over our\r\nseventeen year history. Our primary product is the proprietary T-SPOT\u00ae1.TB test\r\nwhich utilizes our T-SPOT technology platform to test for tuberculosis, which is\r\nthe leading cause of infectious disease death worldwide. Alongside this, we have\r\nalso developed reagents and methods to purify white blood cells for use in\r\nimmunology assays. When used in conjunction with T-SPOT.TB, these reagents\r\nextend blood stability of samples for our test and/or enable workflow automation\r\nfor T-SPOT.TB.\r\n\r\n \r\n\r\nOn November 6, 2018, we completed the sale of our U.S.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f06%2f0001437749-20-004480.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Matthew McLaughlin", "title": "Chief Financial Officer"}, {"name": "Peter James Wrighton-Smith", "title": "Chief Executive Officer & Executive Director"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}